<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id><journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id><journal-id journal-id-type="hwp">pnas</journal-id><journal-id journal-id-type="pmc">pnas</journal-id><journal-id journal-id-type="publisher-id">PNAS</journal-id><journal-title-group><journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title></journal-title-group><issn pub-type="ppub">0027-8424</issn><issn pub-type="epub">1091-6490</issn><publisher><publisher-name>National Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5879690</article-id><article-id pub-id-type="pmid">29531094</article-id><article-id pub-id-type="publisher-id">201719190</article-id><article-id pub-id-type="doi">10.1073/pnas.1719190115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject></subj-group></subj-group><subj-group subj-group-type="heading"><subject>Biological Sciences</subject><subj-group><subject>Biochemistry</subject></subj-group></subj-group></article-categories><title-group><article-title>Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nelp</surname><given-names>Micah T.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kates</surname><given-names>Patrick A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hunt</surname><given-names>John T.</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Newitt</surname><given-names>John A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Balog</surname><given-names>Aaron</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maley</surname><given-names>Derrick</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abell</surname><given-names>Lynn</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Allentoff</surname><given-names>Alban</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Borzilleri</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Hal A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Zeyu</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seitz</surname><given-names>Steven P.</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Chunhong</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9944-5899</contrib-id><name><surname>Groves</surname><given-names>John T.</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="corresp" rid="cor1"><sup>1</sup></xref></contrib><aff id="aff1"><sup>a</sup>Department of Chemistry, <institution>Princeton University</institution>, Princeton, <addr-line>NJ</addr-line> 08544;</aff><aff id="aff2"><sup>b</sup>Immuno-oncology Biology, <institution>Bristol-Myers Squibb Co.</institution>, Princeton, <addr-line>NJ</addr-line> 08543;</aff><aff id="aff3"><sup>c</sup>Molecular Discovery Technologies, <institution>Bristol-Myers Squibb Co.</institution>, Princeton, <addr-line>NJ</addr-line> 08543;</aff><aff id="aff4"><sup>d</sup>Department of Discovery Chemistry, <institution>Bristol-Myers Squibb Co.</institution>, Princeton, <addr-line>NJ</addr-line> 08543;</aff><aff id="aff5"><sup>e</sup>Leads Discovery and Optimization, <institution>Bristol-Myers Squibb Co.</institution>, Princeton, <addr-line>NJ</addr-line> 08543;</aff><aff id="aff6"><sup>f</sup>Department of Radiochemistry, <institution>Bristol-Myers Squibb Co.</institution>, Princeton, <addr-line>NJ</addr-line> 08543</aff></contrib-group><author-notes><corresp id="cor1"><sup>1</sup>To whom correspondence should be addressed. Email: <email>jtgroves@princeton.edu</email>.</corresp><fn fn-type="edited-by"><p>Contributed by John T. Groves, February 12, 2018 (sent for review November 3, 2017; reviewed by Emma L. Raven and Syun-Ru Yeh)</p></fn><fn fn-type="con"><p>Author contributions: M.T.N., P.A.K., J.T.H., J.A.N., A.B., D.M., X.Z., L.A., A.A., R.B., H.A.L., S.P.S., C.Y., and J.T.G. designed research; M.T.N., P.A.K., J.A.N., A.B., D.M., X.Z., A.A., H.A.L., Z.L., S.P.S., and C.Y. performed research; M.T.N., P.A.K., J.T.H., J.A.N., A.B., D.M., X.Z., L.A., A.A., R.B., H.A.L., Z.L., S.P.S., C.Y., and J.T.G. analyzed data; and M.T.N. and J.T.G. wrote the paper.</p></fn><fn fn-type="con"><p>Reviewers: E.L.R., University of Leicester; and S.-R.Y., Albert Einstein College of Medicine.</p></fn></author-notes><pub-date pub-type="ppub"><day>27</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>12</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>3</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>115</volume><issue>13</issue><fpage>3249</fpage><lpage>3254</lpage><permissions><copyright-statement>Copyright &#x000a9; 2018 the Author(s). Published by PNAS.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="vor"/><license-p>This open access article is distributed under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="pnas.201719190.pdf"/><abstract abstract-type="executive-summary"><title>Significance</title><p>Indoleamine 2,3-dioxygenase (IDO1) is a heme protein that catalyzes the dioxygenation of tryptophan. Cells expressing this activity are able to profoundly alter their surrounding environment to suppress the immune response. Cancer cells exploit this pathway to avoid immune-mediated destruction. Through a range of kinetic, structural, and cellular assays, we show that two classes of highly selective inhibitors of IDO1 act by competing with heme binding to apo-IDO1. This shows that IDO1 is dynamically bound to its heme cofactor in what is likely a critical step in the regulation of this enzyme. These results have elucidated a previously undiscovered role for the ubiquitous heme cofactor in immune regulation, and it suggests that other heme proteins in biology may be similarly regulated.</p></abstract><abstract><p>For cancer cells to survive and proliferate, they must escape normal immune destruction. One mechanism by which this is accomplished is through immune suppression effected by up-regulation of indoleamine 2,3-dioxygenase (IDO1), a heme enzyme that catalyzes the oxidation of tryptophan to <italic>N</italic>-formylkynurenine. On deformylation, kynurenine and downstream metabolites suppress T cell function. The importance of this immunosuppressive mechanism has spurred intense interest in the development of clinical IDO1 inhibitors. Herein, we describe the mechanism by which a class of compounds effectively and specifically inhibits IDO1 by targeting its apo-form. We show that the in vitro kinetics of inhibition coincide with an unusually high rate of intrinsic enzyme&#x02013;heme dissociation, especially in the ferric form. X-ray crystal structures of the inhibitor&#x02013;enzyme complexes show that heme is displaced from the enzyme and blocked from rebinding by these compounds. The results reveal that apo-IDO1 serves as a unique target for inhibition and that heme lability plays an important role in posttranslational regulation.</p></abstract><kwd-group><kwd>IDO1</kwd><kwd>heme</kwd><kwd>cancer</kwd><kwd>kynurenine</kwd></kwd-group><funding-group><award-group id="gs1"><funding-source id="sp1">HHS | NIH | National Institute of General Medical Sciences (NIGMS)<named-content content-type="funder-id">100000057</named-content></funding-source><award-id rid="sp1">2R37 GM036298</award-id></award-group><award-group id="gs2"><funding-source id="sp2">Bristol-Myers Squibb (BMS)<named-content content-type="funder-id">100002491</named-content></funding-source><award-id rid="sp2">AWD1004662-BMS/PU</award-id></award-group></funding-group><counts><page-count count="6"/></counts></article-meta></front><body><p content-type="flushleft">Multicellular life is tasked with the immensely complex process of clearing foreign and aberrant cells while preventing autoimmunity. This finely tuned balance is often mediated by enzymes involved in central metabolism, reflecting the ancient origin and strong selective pressure of immune regulation (<xref rid="r1" ref-type="bibr">1</xref>). Indoleamine 2,3-dioxygenase (IDO1) is one such enzyme that oxidizes the essential amino acid tryptophan to produce <italic>N</italic>-formylkynurenine, which is further hydrolyzed to kynurenine (<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r3" ref-type="bibr">3</xref>). This enzyme is present in many tissues and is up-regulated in response to inflammation, specifically the presence of cytokines, such as IFN-&#x003b3;, as well as bacterial lipopolysaccharides (<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r5" ref-type="bibr">5</xref>). Cells expressing IDO1 are able to deplete the inflamed environment of the metabolically expensive substrate, tryptophan, inhibiting the proliferation of immune targets (<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r7" ref-type="bibr">7</xref>).</p><p>IDO1 is also able to serve as an immunosuppressive enzyme. In a seminal paper, IDO1, which was known to be highly expressed in placental tissue, was shown to be essential for the protection of embryos from maternal immune responses. An IDO1 inhibitor, 1-methyl-tryptophan, caused rejection of fetuses capable of provoking the maternal immune response, whereas fetuses closely related to the mother, and thus less likely to provoke an immune response, survived (<xref rid="r8" ref-type="bibr">8</xref>). This remarkable ability of a single enzyme to mediate such complex immune behavior has since been studied in depth, revealing a rich variety of mechanisms by which this enzyme affects immune regulation.</p><p>Expression of IDO1 inactivates surrounding immune cells through the combined effects of low tryptophan and high concentrations of kynurenine (<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r9" ref-type="bibr">9</xref>). T cells are especially sensitive to low tryptophan concentrations, where they undergo cell cycle arrest (<xref rid="r10" ref-type="bibr">10</xref>). Additionally, the downstream metabolites of the product of IDO1 are potent activators of the aryl hydrocarbon receptor through which apoptosis of immune cells can be initiated (<xref rid="r11" ref-type="bibr">11</xref>). IDO1 has further been shown to provide protection from oxidative stress caused by inflammatory processes (<xref rid="r12" ref-type="bibr">12</xref>).</p><p>The importance of IDO1 in precise immune regulation is highlighted by its effects in a variety of processes and disease states, including autoimmune disorders, response to infection, tolerance in transplantation, HIV infection, and blood pressure regulation (<xref rid="r13" ref-type="bibr">13</xref><xref rid="r14" ref-type="bibr"/>&#x02013;<xref rid="r15" ref-type="bibr">15</xref>). This regulation/dysregulation is perhaps most sinisterly manifested in cancer cells that co-opt the immunosuppressive ability of IDO1 to evade immune destruction (<xref rid="r16" ref-type="bibr">16</xref><xref rid="r17" ref-type="bibr"/>&#x02013;<xref rid="r18" ref-type="bibr">18</xref>). The transcriptional control of IDO1 in cancers is often altered through mutation of the Bin1 repressor that allows for vastly up-regulated levels of IDO1 (<xref rid="r19" ref-type="bibr">19</xref>). Tumors displaying high IDO1 activity are associated with poor prognoses (<xref rid="r20" ref-type="bibr">20</xref>). Accordingly, IDO1 is a prime target in the treatment of almost all cancers for which IDO1 inhibition could restore the ability of the immune system to remove these cancer cells on its own or in combination with other treatments (<xref rid="r17" ref-type="bibr">17</xref>). The immunosuppressive effects of IDO1 are also implicated in persistent bacterial infection, wherein IDO1 inhibition has been shown to aid in clearing the infection (<xref rid="r21" ref-type="bibr">21</xref>).</p><p>The mechanism of IDO1 proceeds through a sequential oxygen insertion reaction, where molecular oxygen binds to the ferrous heme and then adds across the C2-C3 double bond of tryptophan through an alkylperoxo intermediate to afford the epoxide with the second atom of molecular oxygen left on the heme in a ferryl compound II structure. This IDO1 ferryl is then proposed to attack the epoxide, breaking the oxygen&#x02013;iron bond and reducing the iron back to the ferrous resting state (<xref rid="r22" ref-type="bibr">22</xref><xref rid="r23" ref-type="bibr"/>&#x02013;<xref rid="r24" ref-type="bibr">24</xref>). This surprising ferryl attack on an epoxide has not been fully explored, as it is not the rate-determining step, but it is consonant with the recent revelations of the reactivity and versatility of compound II in other enzymes (<xref rid="r25" ref-type="bibr">25</xref><xref rid="r26" ref-type="bibr"/>&#x02013;<xref rid="r27" ref-type="bibr">27</xref>).</p><p>Typical of other heme proteins, IDO1 is vulnerable to competitive inhibitors, such as substrate mimics or compounds with heme binding capabilities (<xref rid="r28" ref-type="bibr">28</xref><xref rid="r29" ref-type="bibr"/><xref rid="r30" ref-type="bibr"/>&#x02013;<xref rid="r31" ref-type="bibr">31</xref>). This strategy, however, has suffered from a paucity of inhibitors capable of the specificity and nanomolar binding affinity desirable in a pharmaceutical (<xref rid="r32" ref-type="bibr">32</xref>). Exceptions to this long-standing paradigm have been reported recently that bind to the enzyme without binding directly to the heme iron (<xref rid="r33" ref-type="bibr">33</xref>). We report here an examination of the unique inhibitory modes of two classes of inhibitors that display favorable specificity and robust inhibition of IDO1 (HeLa cell IC<sub>50</sub> = 4.2 and 0.50 nM for compounds <bold>1</bold> and <bold>2</bold>, respectively) (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new"><italic>SI Materials and Methods</italic></ext-link>) (<xref rid="r34" ref-type="bibr">34</xref>).</p><sec id="s1"><title>Heme Cofactor of IDO1 Is Labile</title><p content-type="flushleft">The mechanism of IDO1 inhibition by compounds <bold>1</bold> and <bold>2</bold> (<xref ref-type="fig" rid="fig01">Fig. 1<italic>A</italic></xref>) was interrogated using activity assays with recombinant human IDO1. Compounds <bold>1</bold> and <bold>2</bold>, the latter currently being investigated in phase II clinical trials, are structurally disparate and lack any significant similarity to the substrate tryptophan or any obvious heme binding moieties that could explain their mode of action (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S1</ext-link>). In both cases, these compounds showed an intriguingly slow onset of inhibition, which is inconsistent with a simple competitive mechanism (<xref ref-type="fig" rid="fig01">Fig. 1<italic>B</italic></xref>). Both compounds also showed a clear temperature dependence, only prompting inhibition above 30 &#x000b0;C (<xref ref-type="fig" rid="fig01">Fig. 1<italic>C</italic></xref> and <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S2</ext-link>).</p><fig id="fig01" fig-type="featured" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Time and temperature dependence of IDO1 inhibition. (<italic>A</italic>) Structure of three IDO1 inhibitors. (<italic>B</italic>) IDO1 (2.4 &#x000b5;M) was incubated with compounds <bold>1</bold> (20 &#x000b5;M), <bold>2</bold> (20 &#x000b5;M), or equine apomyoglobin (20 &#x000b5;M) at 37 &#x000b0;C for various times (<italic>x</italic> axis), after which this inhibition was tested using a standard activity assay (<italic>y</italic> axis). (<italic>C</italic>) IDO1 (2.4 &#x000b5;M) was incubated with compounds <bold>1</bold>, <bold>2</bold>, or equine apomyoglobin (20 &#x000b5;M) for 15 min at various temperatures (<italic>x</italic> axis), after which inhibition was tested using a standard activity assay following the rate of <italic>N</italic>-formylkynurenine production (<italic>y</italic> axis). Error bars represent SD. <italic>N</italic> &#x02265; 3.</p></caption><graphic id="gra1" xlink:href="pnas.1719190115fig01"/></fig><p>As a test for IDO1 heme loss as the key initiatory step of inhibition, IDO1 was incubated with apo-myoglobin, which is capable of binding to free heme rapidly and essentially irreversibly, with a binding constant of 10<sup>14</sup> M<sup>&#x02212;1</sup> (<xref rid="r35" ref-type="bibr">35</xref>). Remarkably, IDO1 with added apo-myoglobin was seen to lose activity, interpreted as heme loss to apo-myoglobin, with nearly the same time and temperature dependence as it does with <bold>1</bold> and <bold>2</bold> (<italic>t</italic><sub>1/2</sub> = 17, 14, and 11 min, respectively). This behavior is in contrast to the steadily maintained activity of IDO1 incubated in the absence of inhibitor or apo-myoglobin, indicating that heme binding to IDO1 is a dynamic, reversible process (<xref ref-type="fig" rid="fig01">Fig. 1<italic>B</italic></xref>).</p><p>For a spectroscopic test of heme loss, IDO1 was incubated with a modified version of sperm whale apo-myoglobin, H64YV68F, that, when bound to heme, possesses a unique green color (<xref rid="r36" ref-type="bibr">36</xref>). IDO1 heme loss to apo-myoglobin can thus be conveniently monitored by an increase in absorbance at 600 nm. This confirmed that IDO1 readily loses its heme cofactor (<xref ref-type="fig" rid="fig02">Fig. 2<italic>A</italic></xref> and <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S3</ext-link>) and that this unusual heme lability mirrors the temperature dependence of inhibition by <bold>1</bold> and <bold>2</bold> (<xref ref-type="fig" rid="fig02">Fig. 2<italic>B</italic></xref>). In this way, IDO1 heme loss was shown to be inhibitor-independent and likely the shared rate-determining step of inhibition by <bold>1</bold> and <bold>2</bold>, accounting for the striking similarity of inhibitory profiles for these two distinct inhibitors.</p><fig id="fig02" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Transfer of heme from IDO1 to apomyoglobin. (<italic>A</italic>) The UV-visible spectra of heme transfer from IDO1 (5 &#x000b5;M) to apo-myoglobin H64YV68F (95 &#x000b5;M) over 40 min at 37 &#x000b0;C. (<italic>B</italic>) Heme dissociation from IDO1 (5 &#x000b5;M) to apo-myoglobin H64YV68F (95 &#x000b5;M) at various temperatures as indicated by the increase in absorbance at 600 nm.</p></caption><graphic id="gra2" xlink:href="pnas.1719190115fig02"/></fig></sec><sec id="s2"><title>1 and 2 Bind to IDO1 with Varying Off Rates</title><p content-type="flushleft">The mechanism by which these inhibitors exploit IDO1 heme lability was further explored using <sup>14</sup>C-radiolabeled inhibitors in cold chase experiments. To test whether and how strongly these inhibitors bind to IDO1, the protein was incubated with <sup>14</sup>C-labeled <bold>1</bold> and <bold>2</bold>. These incubations then had natural abundance versions of the inhibitors added, and at various times, the buffer and any unbound inhibitor were exchanged away from the protein using centrifugal concentrators. In this way, any residual inhibitor must be bound to IDO1 and can be quantified using its <sup>14</sup>C radiation. This showed that IDO1 does bind to these compounds, but it does so with very large differences in off rate: <italic>t</italic><sub>1/2</sub> of 2 and 50 min for <bold>1</bold> and <bold>2</bold>, respectively (<xref ref-type="fig" rid="fig03">Fig. 3</xref>). This, despite nearly identical inhibition kinetics, strongly supports heme loss to be the shared and rate-determining step of inhibition.</p><fig id="fig03" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>Cold chase experiments with radiolabeled inhibitors. Radiolabeled versions of <bold>1</bold> (<italic>A</italic>) and <bold>2</bold> (<italic>B</italic>) were incubated with IDO1 followed by introduction of natural abundance <bold>1</bold> and <bold>2</bold>, buffer exchange, and quantification of the residual, IDO1-bound, <sup>14</sup>C-labeled <bold>1</bold> and <bold>2</bold>. Error bars represent SD. <italic>N</italic> = 2.</p></caption><graphic id="gra3" xlink:href="pnas.1719190115fig03"/></fig></sec><sec id="s3"><title>Inhibition Does Not Show a Linear Relationship with Inhibitor Concentration</title><p content-type="flushleft">The concentration dependence of inhibition by <bold>1</bold> and <bold>2</bold> was then examined to illuminate any differences that may indicate a binding event before heme loss. In incubations preceding activity assays, the concentrations of the inhibitors, including apo-myoglobin, were varied from 1 to 16 times that of IDO1, and despite these large differences, the rates of inhibition were nearly identical and certainly far from showing a linear relationship (<xref ref-type="fig" rid="fig04">Fig. 4<italic>A</italic></xref>). These results show that apo-IDO1 formed from intrinsic heme loss is the target for these inhibitors, which must act in some way to block heme from rebinding.</p><fig id="fig04" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4.</label><caption><p>Concentration dependence of IDO1 inhibition. (<italic>A</italic>) IDO1 (2.4 &#x000b5;M) was incubated with various concentrations from 0 to 40 &#x000b5;M (<italic>x</italic> axis) of compounds <bold>1</bold>, <bold>2</bold>, or equine apomyoglobin at 37 &#x000b0;C, and for 15 min after, this inhibition was tested using a standard activity assay (<italic>y</italic> axis). (<italic>B</italic>) The experiment was repeated but with conditions that allow for turnover in the incubation with IDO1 before the activity assay. In this case, IDO1 (2.4 &#x000b5;M) was incubated with 2.4&#x02013;40 &#x000b5;M <bold>1</bold>, <bold>2</bold>, or equine apomyoglobin at 37 &#x000b0;C for 15 min in the presence of 500 &#x000b5;M <sc>l</sc>-tryptophan, 10 mM ascorbate, 10 &#x000b5;M methylene blue, and 10 &#x000b5;g/mL catalase. The rate of <italic>N</italic>-formylkynurenine production was then tested using a standard activity assay (<italic>y</italic> axis). Error bars represent SD. <italic>N</italic> &#x02265; 3.</p></caption><graphic id="gra4" xlink:href="pnas.1719190115fig04"/></fig></sec><sec id="s4"><title>Inhibition Is Independent of IDO1 Turnover</title><p content-type="flushleft">This mechanism predicts that inhibition is independent of activity. To further confirm this hypothesis, we incubated IDO1 with various concentrations of inhibitor and the natural substrate, <sc>l</sc>-tryptophan. Activity was then assessed subsequently. As with all activity experiments described herein, <sc>d</sc>-tryptophan was used as the substrate, which unlike <sc>l</sc>-tryptophan, does not cause substrate inhibition and thus provides for a more convenient, repeatable means of determining activity (<xref rid="r37" ref-type="bibr">37</xref><xref rid="r38" ref-type="bibr"/>&#x02013;<xref rid="r39" ref-type="bibr">39</xref>). In these experiments, any <sc>l</sc>-tryptophan not converted to <italic>N</italic>-formylkynurenine will have been carried over from the incubations and acted as a substrate in addition to the 10 mM <sc>d</sc>-tryptophan (maximum final concentration of 15 &#x003bc;M <sc>l</sc>-tryptophan with a 33&#x000d7; dilution from incubation with inhibitor to activity assay solution). The inhibition profiles were nearly identical, regardless of turnover conditions during incubation with <bold>1</bold> and <bold>2</bold> (<xref ref-type="fig" rid="fig04">Fig. 4<italic>B</italic></xref>). This observation confirms that the mechanism of inhibition is independent of turnover, supporting apo-IDO1 as the target for inhibition and its formation via heme dissociation as the rate-limiting step for this process.</p></sec><sec id="s5"><title>Crystal Structures of IDO1&#x02013;Inhibitor Complexes Reveal Their Mode of Action</title><p content-type="flushleft">The interaction of these inhibitors with IDO1 was clearly elucidated by X-ray crystallographic structures obtained from cocrystallization with <bold>1</bold> and <bold>3</bold>, the latter being a close analog of <bold>2</bold> (<xref ref-type="fig" rid="fig05">Fig. 5</xref>). (Compound <bold>1</bold> is BMS-978587, <bold>2</bold> is BMS-986205, and <bold>3</bold> is BMS-116.) Both inhibitors bound in a manner that displaced the heme cofactor, with each occupying different, although overlapping, space in the vacated heme pocket (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Figs. S4</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">S5</ext-link>). Remarkably, the overall structure of IDO1 bound to each inhibitor was largely unperturbed compared with a heme-containing IDO1 structure (0.61 and 0.44 &#x000c5; rmsd from 2D0T for cocrystal structures with <bold>1</bold> and <bold>3</bold>, respectively). The carboxylate of <bold>1</bold> forms a hydrogen bond with the backbone amide of Ala-264 and with His-346, which ordinarily coordinates with the heme iron on the proximal side. Binding of <bold>1</bold> also led to a shift in the flexible loop made of residues 260&#x02013;265, an event previously observed with the binding of phenylimidazole (<xref rid="r40" ref-type="bibr">40</xref>). The loop shift revealed the putative substrate binding site to the distal face of heme, where the phenylurea group in <bold>1</bold> binds via edge-to-face &#x003c0;-interactions with Tyr-126 and hydrogen bonds with Ser-167. The quinoline of <bold>3</bold> occupies an additional pocket made available by side-chain rearrangements of Phe-270, Phe-214, His-346, and Arg-343 that are stabilized by edge-to-face &#x003c0;-interactions with Phe-270 and a hydrogen bond with Arg-343.</p><fig id="fig05" fig-type="figure" orientation="portrait" position="float"><label>Fig. 5.</label><caption><p>Structure of IDO1&#x02013;inhibitor complexes. (<italic>A</italic>) Superposition of the backbone atoms of the crystal structures of IDO1 holoenzyme (orange) over that of IDO1/<bold>3</bold> (blue). The overall structure of IDO1 undergoes little change on ligand binding. The loop corresponding to residues 260&#x02013;265 is shifted, resulting in significant displacement (measured on C&#x003b1;) of Ser-263 and Ala-264. Moreover, heme-coordinating residue His-346 is slightly rotated to interact with the ligand. (<italic>B</italic>) Sphere representation of <bold>1</bold> overlaid with heme shows that they bind IDO1 in a mutually exclusive manner. Binding geometries are shown for <bold>1</bold> in <italic>C</italic> and <bold>3</bold> in <italic>D</italic>. Structures were prepared from crystallographic coordinates using Maestro software to add hydrogens, determine protonation state of amino acid side chains, and minimize heavy atom deviation to a maximum of 0.3 &#x000c5; from their crystallographic coordinates. Helix S (residues 383&#x02013;399) is hidden in <italic>C</italic> and <italic>D</italic> for clarity. <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Figs. S4</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">S5</ext-link> depict the pocket rendering of holo-IDO1 in comparison with inhibitor-bound structures (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S4</ext-link>), the electron density maps of inhibitors <bold>1</bold> and <bold>3</bold> bound to apo-IDO1 (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S5</ext-link>), and 2D ligand interaction maps for <bold>1</bold> and <bold>3</bold> (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S5</ext-link>).</p></caption><graphic id="gra5" xlink:href="pnas.1719190115fig05"/></fig></sec><sec id="s6"><title>Apo-IDO1 Is Present in Cells</title><p content-type="flushleft">The physiological relevance of apo-IDO1 and its potential as a target for inhibition are supported by previous studies that have shown that IDO1 exists in the apo-form within cells and is capable of activation on addition of exogenous heme (<xref rid="r41" ref-type="bibr">41</xref>). To further support apo-IDO1 as the authentic target of <bold>1</bold> and <bold>2</bold>, additional cellular assays were performed under conditions in which IDO1 was overexpressed but heme concentrations were varied. Briefly, human ovarian cancer cells were treated with IFN-&#x003b3; to induce IDO1 expression. The cells were then tested for IDO1 activity after addition of the ribosomal inhibitor cycloheximide to prevent interference from newly translated IDO1. Cellular IDO1 activity was then assessed after further incubation in the presence or absence of added heme. Despite evidence that IDO1 protein levels were similar (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S6</ext-link>), the activity of those cells with added heme was approximately fivefold higher than that of cells not treated with additional heme, indicating that at least 85% of IDO1 exists in these cells in an apo-form that is capable of activation by exogenously added heme (<xref ref-type="fig" rid="fig06">Fig. 6</xref>). Thus, the target of these inhibitors as revealed in the crystal structures is confirmed to be not only physiologically relevant but also, the predominant form of this enzyme in these cells.</p><fig id="fig06" fig-type="figure" orientation="portrait" position="float"><label>Fig. 6.</label><caption><p>Kynurenine production by human SKOV3 ovarian tumor cells. <italic>Left</italic> depicts results from cells stimulated for 24 h with IFN-&#x003b3; in the absence of added hemin. <italic>Right</italic> depicts cells stimulated with IFN-&#x003b3; in the presence of 40 &#x000b5;M hemin. Blue bars depict kynurenine production after 24 h of IFN-&#x003b3; stimulation. Cells were washed for 1 h with fresh media containing cycloheximide to halt protein synthesis. Kynurenine production was measured 24 h after addition of fresh media devoid of heme (pink) or containing 40 &#x000b5;M hemin (dark blue). Error bars represent SD.</p></caption><graphic id="gra6" xlink:href="pnas.1719190115fig06"/></fig><p>Having established that <bold>1</bold> and <bold>2</bold> compete with heme for apo-IDO1, it was of interest to determine the effect of added heme in the inhibition assays. When 40 &#x000b5;M heme was added to HeLa cells concurrently with stimulation of the cells with IFN-&#x003b3; and inhibition was measured after 20 h of incubation, IC<sub>50</sub> values were shifted less than twofold compared with the same experiment with no added heme (<bold>1</bold>, IC<sub>50</sub> &#x000b1; heme = 7.1/4.2 nM; <bold>2</bold>, IC<sub>50</sub> &#x000b1; heme = 1.1/0.5 nM). The lack of a dramatic heme-dependent potency shift for compound inhibition during the prolonged induction period could result from direct competition for newly synthesized apo-IDO1 between inhibitor and heme, whereby the higher affinity and/or slower off rate of the inhibitors compensate for the higher heme concentration.</p></sec><sec id="s7"><title>Heme Lability Is Dependent on Redox State</title><p content-type="flushleft">The cellular results show that IDO1 heme loss is a major factor in its normal regulation. We found that IDO1 heme lability is strongly dependent on the redox status of iron in the heme cofactor. Using compound <bold>2</bold> to capture apo-IDO1 as it forms from heme loss, we found that ferrous IDO1, which is the resting state of the enzyme in its active form, binds at least 10-fold more tightly to heme than enzyme does in the ferric state, which is catalytically inactive (<xref ref-type="fig" rid="fig07">Fig. 7</xref> and <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S7</ext-link>). This was measured by fitting the loss in absorbance at the corresponding Soret maxima to a single exponential and comparing the half-lives. The kinetics of this loss show that this process is complex and may involve multiple states of heme binding, which will require additional study. The overall difference in heme retention, however, is significant.</p><fig id="fig07" fig-type="figure" orientation="portrait" position="float"><label>Fig. 7.</label><caption><p>Redox state dependence of heme dissociation from IDO1. IDO1 (1.1 &#x000b5;M) was incubated for 40 min at 37 &#x000b0;C in the presence of 10 &#x000b5;M <bold>2</bold>. Heme dissociation from IDO1 was tracked by the loss of absorbance at the IDO1 &#x003bb;<sub>max</sub> of the Soret peak: 404 nm for ferric IDO1 and 425 nm for ferrous IDO1. (<italic>A</italic>) Spectra of ferric IDO1 at various times. <italic>Inset</italic> shows a comparison of the loss in absorbance for both ferric and ferrous IDO1 as a function of time. (<italic>B</italic>) Spectra of ferrous IDO1 at various times. IDO1 was reduced using 5 mM sodium dithionite in a nitrogen-flushed sealed cuvette, and the decay of dithionite can be seen by its decreasing absorption below 375 nm. <italic>Inset</italic> is a scheme showing inhibitor binding to IDO1 in place of heme, causing the observed reduction in absorbance.</p></caption><graphic id="gra7" xlink:href="pnas.1719190115fig07"/></fig><p>A stretch of 20 amino acids missing from electron density of all IDO1 structures has been predicted to form a &#x0201c;closed&#x0201d; state on substrate binding, effectively blocking the solvent-exposed face of heme and introducing an intermolecular hydrogen bond with a heme propionate (<xref rid="r42" ref-type="bibr">42</xref>). It is, therefore, plausible that intracellular tryptophan concentrations also play a role in heme recruitment and retention in IDO1. We tested heme loss from IDO1 to apo-myoglobin H64YV68F in the presence of 0&#x02013;10 mM <sc>l</sc>-tryptophan (the <italic>K</italic><sub>d</sub> of <sc>l</sc>-tryptophan and ferric IDO1 is reported to be 5.8 mM) and found that the rate of heme loss was seen to decrease with increasing substrate concentration (<ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">Fig. S8</ext-link>) (<xref rid="r37" ref-type="bibr">37</xref>). This effect on ferric IDO1 may not be relevant, as intracellular concentrations of tryptophan are unlikely to approach this <italic>K</italic><sub>d</sub> (<xref rid="r43" ref-type="bibr">43</xref>); however, the <italic>K</italic><sub>d</sub> of ferrous IDO1 and <sc>l</sc>-tryptophan is significantly lower, 13 &#x000b5;M (<xref rid="r37" ref-type="bibr">37</xref>), and therefore, it is possible that tryptophan exerts this heme retention effect more strongly on the active, ferrous form of IDO1.</p></sec><sec sec-type="discussion" id="s8"><title>Discussion</title><p content-type="flushleft">The goal of effective and specific inhibition of IDO1 has been intensively pursued since the discovery that this enzyme is critical to cancer&#x02019;s evasion of immune responses (<xref rid="r17" ref-type="bibr">17</xref>). Whereas most inhibitors to date act as competitive inhibitors either by mimicking the substrate tryptophan or by binding to the heme cofactor (<xref rid="r28" ref-type="bibr">28</xref>), <bold>1</bold> and <bold>2</bold> are capable of inhibiting IDO1 by taking advantage of an entirely separate strategy of competing with the heme cofactor itself in binding to the apo-form of the enzyme (<xref ref-type="fig" rid="fig08">Fig. 8</xref>). In the effort to understand the mechanism of this inhibition, the importance of heme lability in IDO1 and its potential as a regulatory mechanism have been more fully revealed.</p><fig id="fig08" fig-type="figure" orientation="portrait" position="float"><label>Fig. 8.</label><caption><p>Catalytic mechanism of tryptophan catabolism by IDO1 and its inhibition via heme dissociation.</p></caption><graphic id="gra8" xlink:href="pnas.1719190115fig08"/></fig><p>The formation of such a large pool of apo-IDO1 is still not fully understood, although it has previously been shown that IDO2, a homolog of IDO1, is capable of down-regulating the activity of IDO1 through heme transfer and sequestration (<xref rid="r44" ref-type="bibr">44</xref>), and it is known that there is significant cross-talk between IDO1 and heme catabolism through heme oxygenase-1, leading to loss of IDO1 activity via heme starvation (<xref rid="r45" ref-type="bibr">45</xref>). It has also been shown that ferrous IDO1 can bind nitric oxide in the absence of tryptophan, inducing rupture of the heme iron-proximal histidine bond to form apo-IDO1 (<xref rid="r46" ref-type="bibr">46</xref>). This transformation bears similarity to the heme receptor of soluble guanylyl cyclase that, although it is part of a signaling process and is not catalytic, uses heme lability in its regulation and is a target for compounds capable of binding to its apo-form (<xref rid="r47" ref-type="bibr">47</xref>, <xref rid="r48" ref-type="bibr">48</xref>).</p><p>We have here shown that heme lability is likely to play a significant role in posttranslational control of IDO1 activity in cells, and the fact that this lability is strongly dependent on the redox state of the heme provides a potential regulatory mechanism to control IDO1 activity. Raven and coworkers (<xref rid="r49" ref-type="bibr">49</xref>) have shown that IDO1 accumulates in the catalytically inactive ferric state during turnover when tryptophan concentrations are low in vitro, and IDO1 is capable of autoxidizing to the ferric state in vivo (<xref rid="r50" ref-type="bibr">50</xref>). Together, these data suggest that IDO1 is self-regulating; under low tryptophan conditions, activity can decrease immediately by conversion to the catalytically inactive ferric state from which it can proceed to the apo-form through heme loss (<xref ref-type="fig" rid="fig08">Fig. 8</xref>). Such a process would contribute to the large pool of apo-IDO1 that serves as the target for these inhibitors.</p><p>Additionally, the complexity seen in the heme loss kinetics, a fast phase followed by a slow phase evident in both assays of heme loss to apomyoglobin H64YV68F and heme loss in the presence of <bold>2</bold> (<xref ref-type="fig" rid="fig02">Figs. 2</xref> and <xref ref-type="fig" rid="fig07">7</xref>), suggests that a simple model of only holo- and apo-IDO1 may not fully encompass this heme loss phenomenon and that there may be intermediate states of heme binding that will require additional study.</p><p>In conclusion, we have shown that IDO1 readily loses heme in a dynamic, reversible, and oxidation state-dependent manner. Targeting the pool of apo-IDO1 provides a means by which a class of inhibitors is capable of effectively inhibiting IDO1 with the potential to restore normal immune clearing of cancerous cells. These results also reveal more fully the intricate metabolic control that can be achieved by modulating the affinity of IDO1 for its heme cofactor and suggest that many other such enzymes could be similarly regulated and mechanistically rich.</p></sec><sec sec-type="materials|methods" id="s9"><title>Materials and Methods</title><p content-type="flushleft">Compounds <bold>1</bold>, <bold>2</bold>, and <bold>3</bold> were prepared at Bristol-Myers Squibb Co. by procedures described in published patent applications (<xref rid="r51" ref-type="bibr">51</xref>, <xref rid="r52" ref-type="bibr">52</xref>). The <sup>14</sup>C-radiolabeled versions of <bold>1</bold> and <bold>2</bold> were provided by Bristol-Myers Squibb Co.</p><p>Protein was expressed and purified using standard methods. Cell-free activity assays were performed using standard methods with an Agilent 8453 diode array spectrometer and temperature-controlled Fisher Scientific isotemp 1016s recirculating chiller. Cold chase experiments using <sup>14</sup>C-radiolabeled <bold>1</bold> and <bold>2</bold> were performed as described in <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new"><italic>SI Materials and Methods</italic></ext-link>. Crystallization conditions used to obtain inhibitor-bound and holo-IDO1 are described in <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new"><italic>SI Materials and Methods</italic></ext-link>. Cell-based activity assays using HeLa and SKOV3 cells were performed as described in <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new"><italic>SI Materials and Methods</italic></ext-link>.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data"><label>Supplementary File</label><media xlink:href="pnas.201719190SI.pdf"/></supplementary-material></sec></body><back><ack><p>We thank Dianlin Xie and Mian Gao for construction of expression vectors; Frank Marsilio, Susan E. Kiefer, and Nicolas Szapiel for early IDO expression and purification work; Yuval Blat, Hao Lu, and Litai Zhang for helpful discussions; Kathy Johnston and Joseph Naglich for assay design in Hela cells; and Alfred Lammens and Stefan Steinbacher (Proteros Biostructures GmbH) for cocrystal structural work with <bold>3</bold>. P.A.K. thanks BMS, Inc. for fellowship support. Support of this work was provided by NIH Grant 2R37 GM036298 (to J.T.G.).</p></ack><fn-group><fn fn-type="COI-statement"><p>Conflict of interest statement: M.T.N., P.A.K., and J.T.G. declare no conflict of interest. X.Z. and L.A. are former employees of Bristol-Myers Squibb Co. J.T.H., J.A.N., A.B., D.M., A.A., R.B., H.L., Z.L., S.P.S., and C.Y. are employees of Bristol-Myers Squibb Co.</p></fn><fn fn-type="other"><p>Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, <ext-link ext-link-type="uri" xlink:href="http://www.wwpdb.org/" xlink:show="new">www.wwpdb.org</ext-link> [PDB ID codes <ext-link ext-link-type="PDB" xlink:href="6AZU" xlink:show="new">6AZU</ext-link> (holoenzyme), <ext-link ext-link-type="PDB" xlink:href="6AZV" xlink:show="new">6AZV</ext-link> (<bold>1</bold>), and <ext-link ext-link-type="PDB" xlink:href="6AZW" xlink:show="new">6AZW</ext-link> (<bold>3</bold>)].</p></fn><fn fn-type="supplementary-material"><p>This article contains supporting information online at <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental" xlink:show="new">www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental</ext-link>.</p></fn></fn-group><ref-list><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munn</surname><given-names>DH</given-names></name><name name-style="western"><surname>Mellor</surname><given-names>AL</given-names></name></person-group><year>2013</year><article-title>Indoleamine 2,3 dioxygenase and metabolic control of immune responses</article-title><source>Trends Immunol</source><volume>34</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">23103127</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Hayaishi</surname><given-names>O</given-names></name></person-group><year>1967</year><article-title>Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes</article-title><source>J Biol Chem</source><volume>242</volume><fpage>5260</fpage><lpage>5266</lpage><pub-id pub-id-type="pmid">6065097</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name><etal/></person-group><year>2003</year><article-title>Comparison of the sequences of Turbo and Sulculus indoleamine dioxygenase-like myoglobin genes</article-title><source>Gene</source><volume>308</volume><fpage>89</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">12711393</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamazaki</surname><given-names>F</given-names></name><name name-style="western"><surname>Kuroiwa</surname><given-names>T</given-names></name><name name-style="western"><surname>Takikawa</surname><given-names>O</given-names></name><name name-style="western"><surname>Kido</surname><given-names>R</given-names></name></person-group><year>1985</year><article-title>Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme</article-title><source>Biochem J</source><volume>230</volume><fpage>635</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">3877502</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>MW</given-names></name><name name-style="western"><surname>Feng</surname><given-names>GS</given-names></name></person-group><year>1991</year><article-title>Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism</article-title><source>FASEB J</source><volume>5</volume><fpage>2516</fpage><lpage>2522</lpage><pub-id pub-id-type="pmid">1907934</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#x000e4;ubener</surname><given-names>W</given-names></name><etal/></person-group><year>2001</year><article-title>Restriction of Toxoplasma gondii growth in human brain microvascular endothelial cells by activation of indoleamine 2,3-dioxygenase</article-title><source>Infect Immun</source><volume>69</volume><fpage>6527</fpage><lpage>6531</lpage><pub-id pub-id-type="pmid">11553600</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curti</surname><given-names>A</given-names></name><name name-style="western"><surname>Trabanelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Salvestrini</surname><given-names>V</given-names></name><name name-style="western"><surname>Baccarani</surname><given-names>M</given-names></name><name name-style="western"><surname>Lemoli</surname><given-names>RM</given-names></name></person-group><year>2009</year><article-title>The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: Focus on hematology</article-title><source>Blood</source><volume>113</volume><fpage>2394</fpage><lpage>2401</lpage><pub-id pub-id-type="pmid">19023117</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munn</surname><given-names>DH</given-names></name><etal/></person-group><year>1998</year><article-title>Prevention of allogeneic fetal rejection by tryptophan catabolism</article-title><source>Science</source><volume>281</volume><fpage>1191</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">9712583</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Baren</surname><given-names>N</given-names></name><name name-style="western"><surname>Van den Eynde</surname><given-names>BJ</given-names></name></person-group><year>2015</year><article-title>Tryptophan-degrading enzymes in tumoral immune resistance</article-title><source>Front Immunol</source><volume>6</volume><fpage>34</fpage><pub-id pub-id-type="pmid">25691885</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munn</surname><given-names>DH</given-names></name><etal/></person-group><year>1999</year><article-title>Inhibition of T cell proliferation by macrophage tryptophan catabolism</article-title><source>J Exp Med</source><volume>189</volume><fpage>1363</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">10224276</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metz</surname><given-names>R</given-names></name><etal/></person-group><year>2012</year><article-title>IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan</article-title><source>OncoImmunology</source><volume>1</volume><fpage>1460</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">23264892</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keskin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>B</given-names></name><name name-style="western"><surname>Munn</surname><given-names>D</given-names></name><name name-style="western"><surname>Mellor</surname><given-names>AL</given-names></name><name name-style="western"><surname>Gearhart</surname><given-names>DA</given-names></name></person-group><year>2007</year><article-title>Decreased protein nitration in macrophages that overexpress indoleamine 2, 3-dioxygenase</article-title><source>Cell Mol Biol Lett</source><volume>12</volume><fpage>82</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">17103092</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Platten</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite</article-title><source>Science</source><volume>310</volume><fpage>850</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">16272121</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><year>2010</year><article-title>Kynurenine is an endothelium-derived relaxing factor produced during inflammation</article-title><source>Nat Med</source><volume>16</volume><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">20190767</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Favre</surname><given-names>D</given-names></name><etal/></person-group><year>2010</year><article-title>Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease</article-title><source>Sci Transl Med</source><volume>2</volume><fpage>32ra36</fpage></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munn</surname><given-names>DH</given-names></name><etal/></person-group><year>2002</year><article-title>Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase</article-title><source>Science</source><volume>297</volume><fpage>1867</fpage><lpage>1870</lpage><pub-id pub-id-type="pmid">12228717</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uyttenhove</surname><given-names>C</given-names></name><etal/></person-group><year>2003</year><article-title>Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</article-title><source>Nat Med</source><volume>9</volume><fpage>1269</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">14502282</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>AJ</given-names></name><etal/></person-group><year>2008</year><article-title>Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase</article-title><source>Proc Natl Acad Sci USA</source><volume>105</volume><fpage>17073</fpage><lpage>17078</lpage><pub-id pub-id-type="pmid">18952840</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>AJ</given-names></name><name name-style="western"><surname>DuHadaway</surname><given-names>JB</given-names></name><name name-style="western"><surname>Donover</surname><given-names>PS</given-names></name><name name-style="western"><surname>Sutanto-Ward</surname><given-names>E</given-names></name><name name-style="western"><surname>Prendergast</surname><given-names>GC</given-names></name></person-group><year>2005</year><article-title>Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</article-title><source>Nat Med</source><volume>11</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">15711557</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munn</surname><given-names>DH</given-names></name><name name-style="western"><surname>Mellor</surname><given-names>AL</given-names></name></person-group><year>2016</year><article-title>IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance</article-title><source>Trends Immunol</source><volume>37</volume><fpage>193</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">26839260</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gautam</surname><given-names>US</given-names></name><etal/></person-group><year>2018</year><article-title>In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis</article-title><source>Proc Natl Acad Sci USA</source><volume>115</volume><fpage>E62</fpage><lpage>E71</lpage><pub-id pub-id-type="pmid">29255022</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis-Ballester</surname><given-names>A</given-names></name><etal/></person-group><year>2009</year><article-title>Evidence for a ferryl intermediate in a heme-based dioxygenase</article-title><source>Proc Natl Acad Sci USA</source><volume>106</volume><fpage>17371</fpage><lpage>17376</lpage><pub-id pub-id-type="pmid">19805032</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basran</surname><given-names>J</given-names></name><etal/></person-group><year>2011</year><article-title>The mechanism of formation of N-formylkynurenine by heme dioxygenases</article-title><source>J Am Chem Soc</source><volume>133</volume><fpage>16251</fpage><lpage>16257</lpage><pub-id pub-id-type="pmid">21892828</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Groves</surname><given-names>JT</given-names></name></person-group><year>December 29, 2017</year><article-title>Oxygen activation and radical transformations in heme proteins and metalloporphyrins</article-title><source>Chem Rev</source><pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00373</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basran</surname><given-names>J</given-names></name><name name-style="western"><surname>Booth</surname><given-names>ES</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><name name-style="western"><surname>Handa</surname><given-names>S</given-names></name><name name-style="western"><surname>Raven</surname><given-names>EL</given-names></name></person-group><year>2016</year><article-title>Analysis of reaction intermediates in tryptophan 2,3-dioxygenase: A comparison with indoleamine 2,3-dioxygenase</article-title><source>Biochemistry</source><volume>55</volume><fpage>6743</fpage><lpage>6750</lpage><pub-id pub-id-type="pmid">27951658</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>R</given-names></name><name name-style="western"><surname>Hofrichter</surname><given-names>M</given-names></name><name name-style="western"><surname>Groves</surname><given-names>JT</given-names></name></person-group><year>2015</year><article-title>Heme-thiolate ferryl of aromatic peroxygenase is basic and reactive</article-title><source>Proc Natl Acad Sci USA</source><volume>112</volume><fpage>3686</fpage><lpage>3691</lpage><pub-id pub-id-type="pmid">25759437</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moody</surname><given-names>PCE</given-names></name><name name-style="western"><surname>Raven</surname><given-names>EL</given-names></name></person-group><year>January 12, 2018</year><article-title>The nature and reactivity of ferryl heme in compounds I and II</article-title><source>Acc Chem Res</source><pub-id pub-id-type="doi">10.1021/acs.accounts.7b00463</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#x000f6;hrig</surname><given-names>UF</given-names></name><name name-style="western"><surname>Majjigapu</surname><given-names>SR</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O</given-names></name></person-group><year>2015</year><article-title>Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</article-title><source>J Med Chem</source><volume>58</volume><fpage>9421</fpage><lpage>9437</lpage><pub-id pub-id-type="pmid">25970480</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis-Ballester</surname><given-names>A</given-names></name><etal/></person-group><year>2017</year><article-title>Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1</article-title><source>Nat Commun</source><volume>8</volume><fpage>1693</fpage><pub-id pub-id-type="pmid">29167421</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malachowski</surname><given-names>WP</given-names></name><etal/></person-group><year>2016</year><article-title>O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1</article-title><source>Eur J Med Chem</source><volume>108</volume><fpage>564</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">26717206</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prendergast</surname><given-names>GC</given-names></name><name name-style="western"><surname>Malachowski</surname><given-names>WP</given-names></name><name name-style="western"><surname>DuHadaway</surname><given-names>JB</given-names></name><name name-style="western"><surname>Muller</surname><given-names>AJ</given-names></name></person-group><year>2017</year><article-title>Discovery of IDO1 inhibitors: From bench to bedside</article-title><source>Cancer Res</source><volume>77</volume><fpage>6795</fpage><lpage>6811</lpage><pub-id pub-id-type="pmid">29247038</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markwalder</surname><given-names>JA</given-names></name><etal/></person-group><year>2017</year><article-title>Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors</article-title><source>Bioorg Med Chem Lett</source><volume>27</volume><fpage>582</fpage><lpage>585</lpage><pub-id pub-id-type="pmid">28003141</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crosignani</surname><given-names>S</given-names></name><etal/></person-group><year>2017</year><article-title>Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and its characterization as a potential clinical candidate</article-title><source>J Med Chem</source><volume>60</volume><fpage>9617</fpage><lpage>9629</lpage><pub-id pub-id-type="pmid">29111717</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>DK</given-names></name><etal/></person-group><year>2018</year><article-title>Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</article-title><source>Bioorg Med Chem Lett</source><volume>28</volume><fpage>732</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">29398543</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargrove</surname><given-names>MS</given-names></name><name name-style="western"><surname>Barrick</surname><given-names>D</given-names></name><name name-style="western"><surname>Olson</surname><given-names>JS</given-names></name></person-group><year>1996</year><article-title>The association rate constant for heme binding to globin is independent of protein structure</article-title><source>Biochemistry</source><volume>35</volume><fpage>11293</fpage><lpage>11299</lpage><pub-id pub-id-type="pmid">8784183</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargrove</surname><given-names>MS</given-names></name><etal/></person-group><year>1994</year><article-title>His64(E7) &#x02192; Tyr apomyoglobin as a reagent for measuring rates of hemin dissociation</article-title><source>J Biol Chem</source><volume>269</volume><fpage>4207</fpage><lpage>4214</lpage><pub-id pub-id-type="pmid">8307983</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sono</surname><given-names>M</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hayaishi</surname><given-names>O</given-names></name></person-group><year>1980</year><article-title>Indoleamine 2,3-dioxygenase. Equilibrium studies of the tryptophan binding to the ferric, ferrous, and CO-bound enzymes</article-title><source>J Biol Chem</source><volume>255</volume><fpage>1339</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">7354029</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>SR</given-names></name></person-group><year>2009</year><article-title>Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase</article-title><source>J Am Chem Soc</source><volume>131</volume><fpage>12866</fpage><lpage>12867</lpage><pub-id pub-id-type="pmid">19737010</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Efimov</surname><given-names>I</given-names></name><etal/></person-group><year>2012</year><article-title>The mechanism of substrate inhibition in human indoleamine 2,3-dioxygenase</article-title><source>J Am Chem Soc</source><volume>134</volume><fpage>3034</fpage><lpage>3041</lpage><pub-id pub-id-type="pmid">22299628</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugimoto</surname><given-names>H</given-names></name><etal/></person-group><year>2006</year><article-title>Crystal structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase</article-title><source>Proc Natl Acad Sci USA</source><volume>103</volume><fpage>2611</fpage><lpage>2616</lpage><pub-id pub-id-type="pmid">16477023</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>SR</given-names></name><etal/></person-group><year>2001</year><article-title>Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-&#x003b3;-activated human macrophages: Posttranslational regulation by pyrrolidine dithiocarbamate</article-title><source>J Immunol</source><volume>166</volume><fpage>6332</fpage><lpage>6340</lpage><pub-id pub-id-type="pmid">11342657</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#x000c1;lvarez</surname><given-names>L</given-names></name><etal/></person-group><year>2016</year><article-title>Structural study of a flexible active site loop in human indoleamine 2,3-dioxygenase and its functional implications</article-title><source>Biochemistry</source><volume>55</volume><fpage>2785</fpage><lpage>2793</lpage><pub-id pub-id-type="pmid">27112409</pub-id></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heidemann</surname><given-names>R</given-names></name><name name-style="western"><surname>L&#x000fc;tkemeyer</surname><given-names>D</given-names></name><name name-style="western"><surname>B&#x000fc;ntemeyer</surname><given-names>H</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>J</given-names></name></person-group><year>1998</year><article-title>Effects of dissolved oxygen levels and the role of extra- and intracellular amino acid concentrations upon the metabolism of mammalian cell lines during batch and continuous cultures</article-title><source>Cytotechnology</source><volume>26</volume><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">22358616</pub-id></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metz</surname><given-names>R</given-names></name><etal/></person-group><year>2014</year><article-title>IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation</article-title><source>Int Immunol</source><volume>26</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">24402311</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: Mutual cross inhibition with indoleamine 2,3-dioxygenase</article-title><source>FASEB J</source><volume>19</volume><fpage>1957</fpage><lpage>1968, and erratum (2006) 20:1573</lpage><pub-id pub-id-type="pmid">16319139</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samelson-Jones</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>SR</given-names></name></person-group><year>2006</year><article-title>Interactions between nitric oxide and indoleamine 2,3-dioxygenase</article-title><source>Biochemistry</source><volume>45</volume><fpage>8527</fpage><lpage>8538</lpage><pub-id pub-id-type="pmid">16834326</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>F</given-names></name><etal/></person-group><year>2010</year><article-title>Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase</article-title><source>J Biol Chem</source><volume>285</volume><fpage>22651</fpage><lpage>22657</lpage><pub-id pub-id-type="pmid">20463019</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fritz</surname><given-names>BG</given-names></name><etal/></person-group><year>2011</year><article-title>Oxidation and loss of heme in soluble guanylyl cyclase from Manduca sexta</article-title><source>Biochemistry</source><volume>50</volume><fpage>5813</fpage><lpage>5815</lpage><pub-id pub-id-type="pmid">21639146</pub-id></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Booth</surname><given-names>ES</given-names></name><name name-style="western"><surname>Basran</surname><given-names>J</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M</given-names></name><name name-style="western"><surname>Handa</surname><given-names>S</given-names></name><name name-style="western"><surname>Raven</surname><given-names>EL</given-names></name></person-group><year>2015</year><article-title>Substrate oxidation by indoleamine 2,3-dioxygenase: Evidence for a common reaction mechanism</article-title><source>J Biol Chem</source><volume>290</volume><fpage>30924</fpage><lpage>30930</lpage><pub-id pub-id-type="pmid">26511316</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vottero</surname><given-names>E</given-names></name><etal/></person-group><year>2006</year><article-title>Cytochrome b(5) is a major reductant in vivo of human indoleamine 2,3-dioxygenase expressed in yeast</article-title><source>FEBS Lett</source><volume>580</volume><fpage>2265</fpage><lpage>2268</lpage><pub-id pub-id-type="pmid">16574111</pub-id></element-citation></ref><ref id="r51"><label>51</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Balog</surname><given-names>JA</given-names></name><etal/></person-group><year>2014</year><comment>Patent Cooperation Treaty Int Appl WO 2014150677</comment></element-citation></ref><ref id="r52"><label>52</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>HP</given-names></name><etal/></person-group><year>2016</year><comment>Patent Cooperation Treaty Int Appl WO 2016073774</comment></element-citation></ref></ref-list></back></article>